Pfizer Interest In Biosimilars Appears To Decline As Firm Ceases To Split Out Segment
Launch Of Humira Challenger In 2023 May Rejuvenate The Area
Pfizer appears to be maintaining its “opportunistic” approach to biosimilars, having ceased to split out the business unit’s results during its Q3 earnings report.
You may also be interested in...
In a year that has seen significant changes throughout our generics and biosimilars industry ranking, the top 10 has welcomed two Indian off-patent leaders after two other firms dropped out of the top table. We delve into what has changed in the first instalment of this year’s Generics Bulletin Top 50.
After a wave of big pharma interest in the biosimilars arena, originator enthusiasm for the sector appears to be waning – potentially opening up an opportunity for newcomers to compete on off-patent biologics.
Prestige says a meeting with the FDA in November represents a “final step” before filing its trastuzumab biosimilar with the US agency by the end of the year. Meanwhile, a major shareholder has invested further in the Singapore-based biosimilars developer.